Research ArticleCANCER

Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models

See allHide authors and affiliations

Science Advances  04 Sep 2019:
Vol. 5, no. 9, eaaw9162
DOI: 10.1126/sciadv.aaw9162

Article Information

vol. 5 no. 9

Online ISSN: 
History: 
  • Received for publication February 5, 2019
  • Accepted for publication August 6, 2019
  • .

Author Information

  1. Mandana T. Manzari1,*,
  2. Grace R. Anderson2,
  3. Kevin H. Lin2,
  4. Ryan S. Soderquist2,
  5. Merve Çakir2,
  6. Mitchell Zhang1,
  7. Chandler E. Moore3,4,,
  8. Rachel N. Skelton3,4,
  9. Maréva Fèvre1,
  10. Xinghai Li1,
  11. Joseph J. Bellucci1,
  12. Suzanne E. Wardell2,
  13. Simone A. Costa1,
  14. Kris C. Wood1,2, and
  15. Ashutosh Chilkoti1,
  1. 1Department of Biomedical Engineering, Duke University, Durham, NC 27710, USA.
  2. 2Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710, USA.
  3. 3Department of Neuroscience, Duke University, Durham, NC 27710, USA.
  4. 4Duke Global Health Institute, Duke University, Durham, NC 27710, USA.
  1. Corresponding author. Email: kris.wood{at}duke.edu (K.C.W.); ashutosh.chilkoti{at}duke.edu (A.C.)
  • * Present address: Memorial Sloan Kettering Cancer Center, 417 E 68th St., New York, NY 10065, USA.

  • Present address: Department of Radiation Oncology, Massachusetts General Hospital, 149 13th St., Charlestown, MA 02129, USA.

Altmetric

Article usage

Article usage: August 2019 to December 2019

AbstractFullPdf
Aug 2019011
Sep 20191412511804
Oct 201936374121
Nov 20191622879
Dec 201939719

Navigate This Article